Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Djuna L. Cahen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6753-4857; OpenAlex author ID A5048322247. Sources: OpenAlex.

Their work

Papers
23 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
67
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 4 papers · 2021: 3 papers · 2022: 7 papers · 2023: 3 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 23

  1. Healthcare expenditures across the care continuum of pancreatic cancer and resected precursor lesions. Co-author DOI 10.1016/j.pan.2026.10.005↗
  2. Pancreatic cancer surveillance: Risk stratification of individuals with a germline CDKN2A pathogenic variant. Co-author DOI 10.1002/ueg2.12662↗
  3. Assessment of Glucose and HbA1c Monitoring in a Pancreatic Cancer Surveillance Program for High-Risk Individuals. Last author DOI 10.14309/ctg.0000000000000777↗
  4. The impact of pancreatic cancer screening on life expectancy: A systematic review of modeling studies. Co-author DOI 10.1002/ijc.34379↗
  5. An 8q24 Gain in Pancreatic Juice Is a Candidate Biomarker for the Detection of Pancreatic Cancer. Co-author DOI 10.3390/ijms24065097↗
  6. Mutation Analysis of Pancreatic Juice and Plasma for the Detection of Pancreatic Cancer. Co-author DOI 10.3390/ijms241713116↗
  7. Protein biomarkers in pancreatic juice and serum for identification of pancreatic cancer. Co-author DOI 10.1016/j.gie.2022.04.1342↗
  8. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals. Co-author DOI 10.1016/j.pan.2022.03.021↗
  9. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2022.04.010↗
  10. Systematic review and meta-analysis: Diagnostic performance of DNA alterations in pancreatic juice for the detection of pancreatic cancer. Last author DOI 10.1016/j.pan.2022.06.260↗
  11. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  12. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Co-author DOI 10.1136/gutjnl-2020-323611↗
  13. Size and Concentration of Extracellular Vesicles in Pancreatic Juice From Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.14309/ctg.0000000000000465↗
  14. Identifying key factors for the effectiveness of pancreatic cancer screening: A model-based analysis. Co-author DOI 10.1002/ijc.33540↗
  15. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic CDKN2A variants. Co-author DOI 10.1136/jmedgenet-2019-106562↗
  16. Neoantigen Quantity and Quality in Relation to Pancreatic Cancer Survival. Co-author DOI 10.3389/fmed.2021.751110↗
  17. Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. Co-author DOI 10.1007/s10689-020-00171-8↗
  18. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  19. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  20. Optimization of Pancreatic Juice Collection: A First Step Toward Biomarker Discovery and Early Detection of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000000939↗
  21. Evolution of features of chronic pancreatitis during endoscopic ultrasound-based surveillance of individuals at high risk for pancreatic cancer. First author DOI 10.1055/a-0574-2396↗
  22. Pancreatic cancer. Co-author DOI 10.1155/2015/809036↗
  23. Prospective assessment of the influence of pancreatic cancer resection on exocrine pancreatic function. First author DOI 10.1002/bjs.9342↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marco J. Bruno · 22 shared papers, 2014–2026 · strength 3.24
  2. Iris J. M. Levink · 12 shared papers, 2020–2024 · strength 1.86
  3. Gwenny Manel Fuhler · 10 shared papers, 2020–2024 · strength 1.64
  4. Brechtje D.M. Koopmann · 7 shared papers, 2021–2024 · strength 1.07
  5. Maikel Petrus Peppelenbosch · 6 shared papers, 2020–2023 · strength 0.94
  6. Kasper A. Overbeek · 7 shared papers, 2020–2022 · strength 0.71
  7. Jeanin Elise van Hooft · 7 shared papers, 2018–2022 · strength 0.68
  8. Inge M.C.M. de Kok · 3 shared papers, 2021–2026 · strength 0.62
  9. Ingrid C. A. W. Konings · 5 shared papers, 2018–2022 · strength 0.52
  10. Isis J. Visser · 3 shared papers, 2022 · strength 0.52
  11. Jihane Meziani · 2 shared papers, 2024 · strength 0.47
  12. Kateryna Nesteruk · 3 shared papers, 2020–2022 · strength 0.44
  13. Femme Harinck · 4 shared papers, 2018–2022 · strength 0.42
  14. Hans F. A. Vasen · 4 shared papers, 2020–2022 · strength 0.40
  15. Lydi M.J.W. van Driel · 3 shared papers, 2020–2022 · strength 0.39
  16. Monique Esther van Leerdam · 2 shared papers, 2022–2024 · strength 0.38
  17. Derk C.F. Klatte · 2 shared papers, 2022–2024 · strength 0.38
  18. Marloes L. J. A. Sprij · 1 shared paper, 2026 · strength 0.28
  19. Marcia Irene Canto · 3 shared papers, 2020–2022 · strength 0.26
  20. Detlef Klaus Bartsch · 3 shared papers, 2020–2022 · strength 0.26
  21. Randall E. Brand · 3 shared papers, 2020–2022 · strength 0.26
  22. Alfredo Carrato · 3 shared papers, 2020–2022 · strength 0.26
  23. Michael Goggins · 3 shared papers, 2020–2022 · strength 0.26
  24. Sapna Syngal · 3 shared papers, 2020–2022 · strength 0.26
  25. Aimee Lee Lucas · 3 shared papers, 2020–2022 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.